Modulation of biological processes in the nucleus by delivery of DNA oligonucleotides conjugated with gold nanoparticles

Biomaterials

Volumn 32, Issue 10, 2011, Pages 2593-2604

  Kim, Dong Wook ^a   Kim, Jae Hong ^a   Park, Mira ^a   Yeom, Ji Hyun ^b   Go, Hayoung ^b   Kim, Sudeok ^b   Han, Min Su ^b   Lee, Kangseok ^b   Bae, Jeehyeon ^a  

^a CHA University   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Alternative splicing; Antisense DNA; Decoy oligonucleotides; Gold nanoparticle; Nucleus

Indexed keywords

ALTERNATIVE SPLICING; ANTISENSE; DECOY OLIGONUCLEOTIDES; GOLD NANOPARTICLE; NUCLEUS;

BIOLOGICAL SYSTEMS; DNA; DRUG THERAPY; GENE TRANSFER; GOLD; MAMMALS; NANOPARTICLES; NUCLEIC ACIDS; OLIGONUCLEOTIDES; TRANSCRIPTION; TUMORS;

GENE THERAPY;

COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; GOLD NANOPARTICLE; OLIGONUCLEOTIDE; PROTEIN BCL 6; PROTEIN MCL 1; PROTEIN P53;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SPLICING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ALTERNATIVE SPLICING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BIOLOGICAL PROCESSES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DNA; DNA, ANTISENSE; GENE TRANSFER TECHNIQUES; GOLD; HUMANS; METAL NANOPARTICLES; MICE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MAMMALIA;

EID: 79251597782     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.11.074     Document Type: Article

References (53)

1. Kamiya H., Tsuchiya H., Yamazaki J., Harashima H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors. Adv Drug Deliv Rev 2001, 52:153-164.
2. Kay M.A., Glorioso J.C., Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001, 7:33-40.
3. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003, 21:117-122.
4. Gardlik R., Palffy R., Hodosy J., Lukacs J., Turna J., Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit 2005, 11:RA110-RA121.
5. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem Rev 2009, 109:259-302.
6. Tekade R.K., Kumar P.V., Jain N.K. Dendrimers in oncology: an expanding horizon. Chem Rev 2009, 109:49-87.
7. Hwang S.J., Davis M.E. Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration. Curr Opin Mol Ther 2001, 3:183-191.
8. Hughes M.D., Hussain M., Nawaz Q., Sayyed P., Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov Today 2001, 6:303-315.
9. Prato M., Kostarelos K., Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008, 41:60-68.
10. Cheon J., Lee J.H. Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology. Acc Chem Res 2008, 41:1630-1640.
11. Slowing I.I., Vivero-Escoto J.L., Wu C.W., Lin V.S. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008, 60:1278-1288.
12. Mironov A.A., Fickett J.W., Gelfand M.S. Frequent alternative splicing of human genes. Genome Res 1999, 9:1288-1293.
13. Faustino N.A., Cooper T.A. Pre-mRNA splicing and human disease. Genes Dev 2003, 17:419-437.
14. Kim E., Goren A., Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008, 24:7-10.
15. Srebrow A., Kornblihtt A.R. The connection between splicing and cancer. J Cell Sci 2006, 119:2635-2641.
16. Sazani P., Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003, 112:481-486.
17. Mann M.J., Dzau V.J. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000, 106:1071-1075.
18. Zhang X., Liu P., Zhang B., Wang A., Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet 2010, 197:46-53.
19. Soppimath K.S., Kulkarni A.R., Aminabhavi T.M. Chemically modified polyacrylamide-g-guar gum-based crosslinked anionic microgels as pH-sensitive drug delivery systems: preparation and characterization. J Control Release 2001, 75:331-345.
20. Grayson A.C., Doody A.M., Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006, 23:1868-1876.
21. Hassani Z., Lemkine G.F., Erbacher P., Palmier K., Alfama G., Giovannangeli C., et al. Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J Gene Med 2005, 7:198-207.
22. Jaaskelainen I., Peltola S., Honkakoski P., Monkkonen J., Urtti A. A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides. Eur J Pharm Sci 2000, 10:187-193.
23. Liu Y., Franzen S. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles. Bioconjug Chem 2008, 19:1009-1016.
24. Tkachenko A.G., Xie H., Liu Y., Coleman D., Ryan J., Glomm W.R., et al. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem 2004, 15:482-490.
25. Kim J.H., Jang H.H., Ryou S.M., Kim S., Bae J., Lee K., et al. A functionalized gold nanoparticles-assisted universal carrier for antisense DNA. Chem Commun (Camb) 2010, 46:4151-4153.
26. Ciribilli Y., Andreotti V., Menendez D., Langen J.S., Schoenfelder G., Resnick M.A., et al. The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. PLoS One 2010, 5:e10236.
27. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
28. Akgul C., Moulding D.A., Edwards S.W. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004, 61:2189-2199.
29. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
30. Opferman J.T., Iwasaki H., Ong C.C., Suh H., Mizuno S., Akashi K., et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005, 307:1101-1104.
31. Bae J., Leo C.P., Hsu S.Y., Hsueh A.J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000, 275:25255-25261.
32. Bingle C.D., Craig R.W., Swales B.M., Singleton V., Zhou P., Whyte M.K. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 2000, 275:22136-22146.
33. Rosi N.L., Giljohann D.A., Thaxton C.S., Lytton-Jean A.K., Han M.S., Mirkin C.A. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006, 312:1027-1030.
34. Shieh J.J., Liu K.T., Huang S.W., Chen Y.J., Hsieh T.Y. Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J Invest Dermatol 2009, 129:2497-2506.
35. Hurst S.J., Lytton-Jean A.K., Mirkin C.A. Maximizing DNA loading on a range of gold nanoparticle sizes. Anal Chem 2006, 78:8313-8318.
36. Fliss A.E., Benzeno S., Rao J., Caplan A.J. Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol 2000, 72:223-230.
37. O'Lone R., Frith M.C., Karlsson E.K., Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004, 18:1859-1875.
38. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-6311.
39. Lu X., Lane D.P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes?. Cell 1993, 75:765-778.
40. Shieh S.Y., Taya Y., Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J 1999, 18:1815-1823.
41. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
42. Berry M., Nunez A.M., Chambon P. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci U S A 1989, 86:1218-1222.
43. Nikiforov M.A., Riblett M., Tang W.H., Gratchouck V., Zhuang D., Fernandez Y., et al. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A 2007, 104:19488-19493.
44. Shukla R., Bansal V., Chaudhary M., Basu A., Bhonde R.R., Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir 2005, 21:10644-10654.
45. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1:325-327.
46. Giljohann D.A., Seferos D.S., Patel P.C., Millstone J.E., Rosi N.L., Mirkin C.A. Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles. Nano Lett 2007, 7:3818-3821.
47. Klinck R., Bramard A., Inkel L., Dufresne-Martin G., Gervais-Bird J., Madden R., et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res 2008, 68:657-663.
48. Venables J.P., Klinck R., Bramard A., Inkel L., Dufresne-Martin G., Koh C., et al. Identification of alternative splicing markers for breast cancer. Cancer Res 2008, 68:9525-9531.
49. Winkler J., Stessl M., Amartey J., Noe C.R. Off-target effects related to the phosphorothioate modification of nucleic acids. ChemMedChem 2010, 5:1344-1352.
50. Morishita R., Higaki J., Tomita N., Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998, 82:1023-1028.
51. Igawa K., Satoh T., Yokozeki H. A therapeutic effect of STAT6 decoy oligodeoxynucleotide ointment in atopic dermatitis: a pilot study in adults. Br J Dermatol 2009, 160:1124-1126.
52. Sen M., Tosca P.J., Zwayer C., Ryan M.J., Johnson J.D., Knostman K.A., et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2009, 63:983-995.
53. Sumi K., Yokozeki H., Wu M.H., Satoh T., Kaneda Y., Takeda K., et al. In vivo transfection of a cis element 'decoy' against signal transducers and activators of the transcription 6 (STAT6) binding site ameliorates the response of contact hypersensitivity. Gene Ther 2004, 11:1763-1771.